Drug resistance monitoring: combined rates may be the best indicator of programme performance.
D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001459:Bangladesh / Q000453:epidemiology; D003906:Developing Countries; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D017720:Molecular Epidemiology; D008991:Monitoring, Physiologic; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D011159:Population Surveillance; D015995:Prevalence; D011322:Primary Prevention / Q000458:organization & administration*; D015397:Program Evaluation; D012008:Recurrence; D012189:Retrospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control*
D000995:Antitubercular Agents